Novel Cell_cycle>cell cycle inhibitor

Dual thymidylate synthase and dihydrofolate reductase inhibitor

Novel inhibitor of Mycobacterium marinum MelF (Rv1936), exhibiting bacteriostatic/bactericidal activity against M. marinum and M. tuberculosis in vitro

Selective sphingosine kinase 1 (SK1) inhibitor

Novel inhibitor of HIV-1 entry

Novel inhibitor of Mycobacterium marinum MelF (Rv1936), exhibiting bacteriostatic/bactericidal activity against M. marinum and M. tuberculosis in vitro

Selective inhibitor of Adenylyl Cyclase isoform-2 (AC2)

Novel inhibitor of HIV-1 gene expression

Novel potent inhibitor of filamentation and biofilm formation by the Candida albicans SC5314 strain

Novel inhibitor of Mycobacterium marinum MelF (Rv1936), exhibiting bacteriostatic/bactericidal activity against M. marinum and M. tuberculosis in vitro

Novel Protein kinase A and B inhibitor

The first clickable, photoreactive probe that inhibits both γ-secretase and PSase activities and specifically labels PS1-NTF and signal peptide peptidase (SPP)

Novel cell-permeable, potent, reversible, and substrate competitive LSD1 inhibitor, promoting the adipogenic differentiation of hESCs

Novel inhibitor of viral transcriptional elongation, blocking both HIV-1 replication and reactivation

NF-kappa B (NF-kB) inhibitor and p53 activator

Novel selective inhibitor of KDM4s, inhibiting all members of the KDM4(A-E) subfamily

Novel KDM4 inhibitor, inhibiting equally all members of the KDM4 family and exhibiting modest selectivity over other JmjC-KDMs including KDM2A and PHF8

Novel Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα -related Diseases

The first Gatekeeper RXR antagonist that does not show allosteric inhibition in permissive RXR heterodimers, binding domain (LBD) at the entrance of the ligand binding pocket (LBP), blocking access to the LBP and thus serving as a gatekeeper

FTY720 derivative

Novel inhibitor of the E2 ubiquitin-conjugating enzyme Cdc34A

Novel Cereblon modulator, promoting ZBTB16 degradation by primarily engaging distinct structural degrons on CRBN-ZnF1 zinc finger domains

PqsE inhibitor, binding to the active center inhibiting PqsE's thioesterase activity in cell-based and in vitro assays

PqsE inhibitor, binding to the active center inhibiting PqsE's thioesterase activity in cell-based and in vitro assays

Novel potent orally bioavailable Syk kinase inhibitor

Novel Cereblon modulator, promoting ZBTB16 degradation by primarily engaging distinct structural degrons on CRBN-ZnF3 zinc finger domains

Novel Indigoid Anti-tuberculosis Agent; Antimicrobial

Novel coupleable ceritinib analog with a linker, also binding multiple other kinases, including FAK1, RSK1/2, ERK1/2, CAMKK2 and FER

Novel Inhibitor of TonB Function

Novel Inhibitor of TonB Function

Potent photoprobe as Rho/MKL1/SRF transcription inhibitor

Novel inhibitor of G Protein-Coupled Receptor Kinase

Novel covalent selective GRK inhibitor, interacting with a nonconserved cysteine (Cys474)

Novel sialyltransferase inhibitor (IC 50 : 2 µM)

Novel MmpL3 inhibitor

(E/Z)-CCR-11 (Comp 12) is a selective CD38 inhibitor, with an IC50 of 20.8 μM against CD38 cyclase. (E/Z)-CCR-11 promotes increases in cellular NAD+ levels and interferon γ.

Novel CCR4 antagonist, enhancing DC activation and homing to the regional lymph node and showing potent vaccine adjuvant activity through the inhibition of regulatory T-cell recruitment

Novel dual FLT3/Aurora A inhibitor, overcoming D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells

Inactive analogue of pictilisib to be used as the negative control

Highly Selective Oral Checkpoint Kinase 1 (CHK1) Inhibitor

Novel inhibitor of BCL6

Novel inhibitor of the efflux function of ABCG2, selectively reversing ABCG2-mediated MDR in cancer cells in vitro and in vivo

Novel potent covalent BRD4 degrader, degrading BRD4 in a proteasome- and RNF4-dependent manner without inhibiting RNF4 autoubiquitination activity

Novel MC1R agonist

Novel Caspase-1 inhibitor

Novel telomerase inhibitor

Retinoic acid receptor beta (RARbeta) agonist, overcoming inhibition of axonal outgrowth via phosphoinositide 3-kinase signalling in the injured adult spinal cord.

Novel CD22 glycan ligand, targeting CD22-expressing B cells, uptaking and enhancing siRNA gene expression knockdown via formation of CD22 glycan ligand-conjugated siRNA

Novel CD33 pre-mRNA splicing modulator, increasing exon 2 skipping in cellular mRNA pools

Novel agonist for the vitamin D receptor (VDR)

Novel agonist for the vitamin D receptor (VDR)

Novel agonist for the vitamin D receptor (VDR)

Novel selective cdDHQD inhibitor

Novel potent and selective CDK12 inhibitor

Potent, ATP-binding site-targeting Cdk4/D1 inhibitor

Novel potent CDK6 degrader

Novel potent and balanced dual CDK6/PIM1 inhibitor, showing high kinase selectivity and displaying stronger potency in reducing the burden of AML than palbociclib and SMI-4a in vivo

Novel potent CDK8 inhibitor

Novel potent and selective dual inhibitor of CDK8 and CDK19

Potent dual inhibitor of CDK8/19, suppressing phosphorylated STAT1 in various cancer cells

Novel potent and selective inhibitor of CDK8, also modulating CDK19

Novel inhibitor of CDK8

Novel highly potent, selective, permeable CDK8 inhibitor

Novel potent and highly selective CDK8 inhibitor, with no apparent potential for time-dependent CYP3A4 inhibition

Novel potent CDK8 inhibitor

Novel CDK8 inhibitor

Novel CDK8 inhibitor

Novel CDK8 inhibitor

Novel Potent and Selective CDK9 Degrader for Targeting Transcription Regulation in Triple-Negative Breast Cancer

Novel potent dual inhibitor of CDK9 and BET proteins with balanced activities of BRD4 (IC50 = 12.7 nM) and CDK9 (IC50 = 22.4 nM), as well as good antiproliferative activities on a small cancer cell panel

Highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity

Novel inhibitor of the cyclin-dependent kinase 9 (CDK9)

Potent and selective ATP competitiive inhibitor of cycB-CDK1, cycE-CDK2, and cycD1-CDK4

Novel potent inhibitor of cyclin-dependent kinases (CDKs) 2, 5, and 9, displaying activities across more than 60 cancer cell lines

Novel photoaffinity probe for cyclin-dependent kinase (CDK) family

Novel anti-hepatitis B virus (HBV) agent

Highly permeable non-Pglycoprotein substrate

Potent Antagonist for the Human Thyrotropin Receptor (TSHR)

Novel highly selective inhibitor of multidrug resistance protein 4 (MRP4)

First-generation cephalosporin antibiotic and interleukin 15 inhibitor, specifically interacting with interleukin 15 (IL-15) receptor subunit α (IL-15Rα) and to inhibit IL-15-dependent TNF-α and IL-17 synthesis, showing inhibitory activity against all of

Third-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity

Second-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity

Broad-spectrum, beta-lactamase-resistant, second-generation cephalosporin antibiotic, inhibiting bacterial cell wall synthesis via inhibition of cross-linking of peptidoglycans

Third-generation broad spectrum antibiotic against both gram-positive and gram-negative microorganisms

Fourth-generation cephalosporin

Broad-spectrum fourth-generation cephalosporin antibiotic

beta-Lactamase-stable, broad-spectrum, third-generation cephalosporin antibiotic with antibacterial activity

Broad-spectrum, fifth-generation cephalosporin antibiotic, inactivating penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall

Novel modulator of cell death signal transduction pathways, reducing the cytotoxicity of anthrax lethal toxin (LT)

Novel highly selective TAF1 inhibitor

Novel potent ALK inhibitor. also inhibiting the insulin receptor

Novel potent ALK inhibitor

Prodrug of CEP-751 (KT-6587) as antitumor agent, inhibiting protein kinases

Novel potent, selective, and orally bioavailable inverse agonist of the histamine H 3 receptor (H 3 R)

Novel selective inhibitor of the nuclear enzymes poly(ADP-ribose) polymerase (PARP) 1 and 2

Natural disrupter of RNA G-quadruplexes, inhibiting G-quadruplex-dependent alternative splicing, stimulting the stomach lining and inducing vomiting

Novel small molecule prodrug for use with SEAKER cells, exhibiting enhanced anticancer activity

Novel probe for cellulose synthase trafficking, inhibiting cellulose deposition and interferes with the trafficking of cellulose synthase complexes and their associated proteins KORRIGAN1 and POM2/CSI1

Novel Probe for the High Temperature Requirement A (HTRA) Serine Proteases

Novel non-steroid reversible dual inhibitor of CYP17 and CYP11B2 against prostate cancer with fewer cardiac side effects

Potent inhibitor of TTK kinase

Novel Highly Potent, Selective, Bioavailable TTK (threonine tyrosine kinase) Inhibitor

Novel GSK3 inhibitor, inducing cell death through cyclin D1 depletion in breast cancer cells

Novel inducer of neural differentiation and growth arrest in human primary GBM-derived cells, playing a tumor-suppressive role via cAMP/CREB signaling pathway

Novel PRL-3 inhibitor, blocking the migration and invasion of metastatic cancer cells

CGA-JK3 is CGA-JK3 is an ATP-competitive inhibitor of IKKβ-catalyzed kinase activity. CGA-JK3 inhibits IκBα phosphorylation in LPS (HY-D1056) - induced RAW 264.7 cells.

Novel functional Gboxin analogue that is suitable for live-cell ultraviolet crosslink conjugation and click chemistry

Novel Bruton's tyrosine kinase (BTK) inhibitor

Novel inhibitor of Wnt/β-catenin signaling; Anticancer agent promoting PKCα-mediated β-catenin phosphorylation/degradation

Non-peptide tachykinin NK1 receptor antagonist

Activator of RORalpha, inducing growth arrest in androgen-independent DU 145 prostate cancer cells

Novel HIV-1 protease inhibitor, also potently inhibiting major aspartyl peptidase 1 (May1), a secreted Cryptococcus neoformans protease

Peptoid Tat/transactivation response element inhibitor, inhibiting human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry

Liver specific thyromimetic agonist of thyroid hormone receptor-

Broad spectrum matrix metalloproteinase (MMP) inhibitor

Mutant firefly luciferase variant with enhanced light emission

Matrix metalloproteinase (MMP) inhibitor

Water soluble CycLuc3, mutant firefly luciferase variant with enhanced light emission

Benzodiazepine antagonist

Benzodiazepine receptor partial agonist

The first small-molecule based MCM2-targeted NIR-II probe

Novel Highly Potent and Selective Cholesterol 24-Hydroxylase (CH24H) Inhibitor

Novel microtubule polymerization inhibitor with little susceptible to transporter-mediated chemoresistance

Novel Hsp90 inhibitor

Potent Androgen_receptor>androgen receptor (AR) pure antagonist which did not produce the agonist metabolite

Novel Hsp90 inhibitor

Novel inhibitor of mitochondrial respiration, targeting drug-resistant cancer cells with stem-like features by inhibiting mitochondrial respiration complex I (NADH:ubiquinone oxidoreductase, complex I [CI])

The desmethyl precursor of CHDI-180R which is a first-in-class high-affinity PET imaging ligand specific for mHTT aggregates

Novel potent and selective kynurenine mono-oxygenase (KMO) inhibitor

Novel intracellular chelator, disrupting iron homeostasis in bacteria

Novel inhibitor against Lactate Dehydrogenase (LDH) of Cryptosporidium parvum

Inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase

Novel potent and orally active ChemR23 inhibitor (IC 80 = 12 nM), showing a long-acting effect in cynomolgus monkeys

Novel dual inhibitor of cholinergic dysfunction and amyloid deposition for AD treatment, penetrating the blood-brain barrier (BBB) and enhancing the cerebral acetylcholine level

Novel acetylcholinesterase inhibitor

Potent, tissue-selective estrogen receptor modulator

Potent, long-acting, and selective muscarinic M3 receptor antagonist

Novel Potent and Selective Chikungunya Virus Envelope Protein Inhibitor

Novel potent inhibitor of HIV-1 integrase

Antiviral and antifungal agent

Widely used biocidal agent

Sympathomimetic agent, facilitating the release of catecholamines, especially noradrenaline and dopamine, from nerve terminals in the brain and also inhibiting their uptake

Serotonin transporter substrate

Hydrophilic prodrug of CHM-1

Novel potent and highly selective irreversible Brutons tyrosine kinase (BTK) inhibitor, inhibiting BTK Y223 auto-phosphorylation

Potent and selective FLT3 inhibitor

Novel Potent Fms-like Tyrosine Kinase 3 Internal Tandem Duplications (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia

Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors

Antioxidant; Aldose reductase inhibitor

Natural phytosterol, showing antidiabetes activities

Potent and selective partial agonist of ecdysone receptor (EcR)

Novel potent BMP potentiator with osteogenic efficacy, enhancing canonical BMP outputs at the expense of TGFβ-Smads in an unprecedented manner

Novel inhibitor of 6-hydroxydopamine induced apoptosis in SH-SY5Y cells via mitochondria protection and NF-κB modulation

Novel inhibitor of superoxide anion (O2(-)) generation; Inhibitor of phospholipase D activation; Modulator of immune cell migration via RhoA activity inhibition; Inhibitor of Rac2 activation in stimulated neutrophils

Novel Non-peptide GLP-1R Agonist, adopting a unique binding mode with a more open receptor conformation at the extracellular face

Novel chymase inhibitor, exhibiting concentration-dependent chymase inhibitory activity

Novel inhibitor of E3 ligase activity of cIAP1, antagonizing c-MYC by stabilizing MAD1 protein in cells

Novel SOCE modulator, displaying selectivity over other calcium channels, such as TRPV1, TRPM8, and voltage-operated calcium channels

Stimulator of nitric oxide release and scavenger of superoxide

Novel Selective Agonist of GPR55

Novel Selective Agonist of GPR55

HIV-1 Rev pre-integration inhibitor

Novel specific anti-VEEV (Anti-Venezuelan Equine Encephalitis Virus) agent

Novel inhibitor against the NS3/4A serine protease of Hepatitis C virus genotype 3

Novel Selective Agonist of GPR55

Antibacterial agent, being effective in treating dapsone resistant leprosy

Blocker of integrin binding to its endothelial receptor (VCAM-1)

Novel inhibitor of Cdc42 that act by blocking nucleotide binding with no effect on RhoA or Rac

Novel lopinavir analogue against COVID-19, forming the most stable complex with the Mpro

Novel Inhibitor of the Major Facilitator Superfamily (MFS) of Efflux Pump Transporters.

Potent inhibitor of cancer cell growth with microtubule-binding activity

Potent inhibitor of ROCK2 enzymatic activity

Novel Stimulator of Hepatitis C Virus NS3 Helicase-Catalyzed ATP Hydrolysis

Potent inhibitor of HIV-1 nucleocapsid (NC)-DNA interaction; specifically bound NC with nanomolar affinity, and showed modest anti-HIV-1 activity in ex vivo cell assays

Potent inhibitor of cancer cell growth with microtubule-binding activity

Novel specific inhibitor of bacterial AddAB helicase-nuclease DNA repair enzyme

Inhibitor of PLAP and TNAP

Inhibitor of human tyrosyl-DNA phosphodiesterase 1 (TDP1); Delayed death inhibitor of the malarial parasite plastid; Inhibitor of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1); Inhibit

Platelet activation inhibitor

Novel 3C-like protease inhibitor of SARS-CoV-2

Altered peptide ligand containing a novel CD4 T-cell epitope of human heat shock protein 60 (83-109)

Cell permeable caged inositol triphosphate, promoting Ca2+-release from internal stores under UV photolysis

Noncompetitive inhibitor of Candida albicans growth and activity of (1-3)-beta-glucan synthase

ß-Adrenergic agonist

5-HT2 antagonist

Agonist of the 5-HT1 and 5-HT4 receptors and as an antagonist of the 5-HT2 receptors

Novel modulator of SLC6A19, robustly, selectively, and reproducibly inhibiting SLC6A19

Broad-spectrum antimicrobial carboxyfluoroquinoline, interfering with the bacterial DNA gyrase, inhibiting the DNA synthesis, and preventing bacterial cell growth

Non-Specific Anticoagulant Reversal Agent

Positive modulator of GABA A receptors

Potent inhibitor of MRSA PK

JBP923 analog, exerting potent therapeutic effect on inflammatory bowel disease (IBD)

Novel, natural auxin efflux inhibitor, promoting lateral root formation

Negative control for VZ185

Polo-like kinase 1 (Plk1) inhibitor

Novel Cell-Permeable STAT3 Inhibitor, targeting the SH2 domain

Biological Active Reagents

Potent and competitive antagonist at the human D3 receptor

Novel potent muscarinic antagonist wirh antimuscarinic antidepressant-like activities, showing modest affinity across the mAChRs when compared to L-687306 and scopolamine

SecA inhibitor, showing antiprotozoal, antibacterial and antifungal effects, inhibiting post-translational protein transport into the endoplasmic reticulum. also Inhibiting ATP-dependant translocation of precursor proteins acrossing a bacterial cell membr